The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy

MLA

Francis Proulx-Rocray, et al. “The Prognostic Impact of KRAS, TP53, STK11 and KEAP1 Mutations and Their Influence on the NLR in NSCLC Patients Treated with Immunotherapy.” Cancer Treatment and Research Communications, vol. 37, no. 100767-, Jan. 2023. EBSCOhost, https://doi.org/10.1016/j.ctarc.2023.100767.

APA

Francis Proulx-Rocray, Bertrand Routy, Rami Nassabein, Wiam Belkaid, Danh Tran-Thanh, Julie Malo, Marion Tonneau, Omar El Ouarzadi, Marie Florescu, Mustapha Tehfe, & Normand Blais. (2023). The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy. Cancer Treatment and Research Communications, 37(100767-). https://doi.org/10.1016/j.ctarc.2023.100767

Chicago

Francis Proulx-Rocray, Bertrand Routy, Rami Nassabein, Wiam Belkaid, Danh Tran-Thanh, Julie Malo, Marion Tonneau, et al. 2023. “The Prognostic Impact of KRAS, TP53, STK11 and KEAP1 Mutations and Their Influence on the NLR in NSCLC Patients Treated with Immunotherapy.” Cancer Treatment and Research Communications 37 (100767-). doi:10.1016/j.ctarc.2023.100767.